News >

Ramucirumab Extends Survival in Advanced HCC

Published: Wednesday, Jun 06, 2018

Dr Andrew X. Zhu

Andrew X. Zhu, MD, PhD
Second-line ramucirumab (Cyramza) reduced the risk of death by 29% versus placebo in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP), according to results from the phase III REACH-2 trial presented at the 2018 ASCO Annual Meeting.1 

The median overall survival (OS) was 8.5 months with ramucirumab versus 7.3 months with placebo (HR, 0.710; 95% CI, 0.531-0.949, P = .0199) among patients with progression on or intolerance to first-line treatment with sorafenib (Nexavar). Survival in both groups exceeded statistical assumptions of the trial design (4.7 months with placebo, improved to 6.5 months with ramucirumab). 

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x